We have used electrophysiology in brain slices and the cylinder test to examine the effect of CIQ on glutamatergic synaptic transmission, synaptic plasticity, and forelimb-use in the unilateral 6-hydroxydopamine-lesion mouse model of PD.
| INTRODUCTION
Parkinson's disease (PD) is characterized by a dramatic reduction in the content of dopamine in the striatum and a progressive degeneration of dopaminergic neurons in the substantia nigra.
1
As a consequence of dopamine loss, glutamatergic neurotransmission is altered.
2 Amantadine, a noncompetitive antagonist at the N-methyl-d-aspartate (NMDA) type of glutamate receptor (NMDAR), is used in the treatment of particular motor symptoms as well as dyskinesia induced by levodopa treatment. Because the beneficial actions of amantadine are associated with unwanted side effects, subunit-specific NMDAR antagonists were suggested as alternative strategies for therapeutic intervention in PD. 3 NMDARs are heteromeric assemblies of at least one GluN1 subunit and other GluN2 (A-D) and GluN3 (A, B) subunits. Functional and pharmacological properties of NMDARs are determined by the GluN2 subunits they contain. 4, 5 Although GluN2B-containing NMDAR antagonists reverse motor symptoms in animal models of PD, these compounds failed to provide clear benefit in PD patients. 6, 7 Targeting the other GluN2 subunits that compose NMDARs in the basal ganglia might suggest alternative therapeutic strategies for treatment of PD.
In the striatum of adult humans and rodents, the expression of GluN2A is moderate, that of GluN2B is high, GluN2C is scarce, and
GluN2D is expressed in some classes of interneurons. Medium spiny projection neurons (MSNs), which represent 95% of the total striatal population, express high levels of GluN2B and moderate levels of GluN2A. 8 Large aspiny cholinergic interneurons in the striatum express moderate levels of GluN2A, GluN2B, and GluN2D. [8] [9] [10] In the striatum of animal models of PD, the expression of GluN2A is unaffected but that of GluN2B is decreased. 8, [11] [12] [13] [14] GluN2D is reduced in striatal cholinergic interneurons, and a switch between GluN2B and GluN2D occurs in projection neurons. [15] [16] [17] These studies suggest that neuronal adaptations that occur in the dopamine-depleted striatum involve a change in the subunit composition of NMDARs and an altered role of these receptors in NMDAR-dependent forms of synaptic plasticity.
Long-term changes in glutamatergic synaptic strength are potential candidates for cellular mechanisms of learning and memory. 18 In the striatum, long-term potentiation (LTP) and long-term depression (LTD) are believed to underlie motor learning. NMDARs, in particular those containing GluN2A, 19 are involved in LTP, but not LTD, induction in the striatum. [20] [21] [22] Several studies have shown that LTP and LTD are lost in the striatum of animal models of PD and that aberrant synaptic plasticity occurs in models of L-DOPAinduced dyskinesia. 2, 20, [23] [24] [25] Loss of LTP likely results from reduced content of dopamine in the striatum, but the possibility exists that an overall reduced function of NMDARs in the dopamine-depleted striatum contributes to the inability to induce LTP, despite an upregulation of GluN2D in MSNs. Recent studies suggest a potential benefit in potentiating GluN2D-containing NMDARs in experimental Parkinsonism. Thus, using the positive allosteric modulator of GluN2C/D-containing NMDARs, CIQ, 26 we found that dopamine release from residual axon terminals was enhanced in the partially dopamine-depleted striatum. 27 These observations suggest a potential way to rescue neurochemical deficits in early, presymptomatic stages of PD, when a proportion of dopamine neurons are still functioning, by modulating the activity of GluN2D-containing
NMDARs. Whether potentiation of GluN2D-containing NMDARs with CIQ rescues other dopamine-dependent deficits remains to be examined.
The aims of our study were to examine if CIQ rescues the loss of LTP in the striatum and deficits in paw usage (forelimb-use asymmetry), in the unilateral 6-hydroxydopamine (6-OHDA)-lesioned mouse model of PD. Our results demonstrate improvement of both neurophysiological and behavioral deficits by positive allosteric modulation of GluN2C/2D-containing NMDARs with CIQ.
| METHODS

| Animals
Experiments were approved by our local ethical committee (Stockholms norra djurförsöksetiska nämnd) and were performed as described previously. 15, 28 All efforts were made to minimize animal suffering. We used male C57Bl/6 mice aged 4-9 weeks (Janvier Labs, Le Genest-Saint-Isle, France). Mice were maintained on a 12:12 hours light/dark cycle and had free access to food and water. Control mice did not undergo surgery prior to the experiments. Another group of mice underwent unilateral stereotaxic injection of the toxin 6-OHDA in the substantia nigra pars compacta to produce degeneration of dopaminergic neurons and dopamine depletion of the striatum. These mice were anesthetized with intraperitoneal (i.p.) injection of 80 mg/kg ketamine and 5 mg/kg xylazine, placed in a stereotaxic frame, and injected, over 2 minutes, with 3 μg of 6-OHDA in 0.01% ascorbate into the substantia nigra pars compacta of the right hemisphere. The coordinates for injection were AP: −3 mm;
ML: −1.1 mm; and DV: −4.5 mm relative to bregma and the dural surface. 29 Mice were allowed to recover from the surgery for 1-3 weeks before they were used for electrophysiological and behavioral experiments. The severity of the lesion induced by 6-OHDA was analyzed
by Western blotting and immunodetection of the protein amounts of tyrosine hydroxylase (TH), the rate-limiting enzyme in the synthesis of dopamine as described previously. 15, 16, 27, 30 For the mice used in the experiments presented in Figures 1 and 2 , the levels of TH in the lesioned striatum were reduced to 29.7 ± 6.5% of the levels in the intact striatum (n = 29 mice 
| Electrophysiology in brain slices
Mice underwent cervical dislocation followed by decapitation. Their brains were rapidly removed, and coronal brain slices (400 μm thick)
containing the striatum and the overlying cortex were prepared with a microslicer (VT 1000S; Leica Microsystem, Heppenheim, Germany).
Slices were incubated, for at least 1 hour, at 32°C in oxygenated 
| Cylinder test
We examined the effect of acute and chronic i.p. injections of CIQ on forelimb-use in the cylinder test. Mice were lesioned as described above and received an i.p. injection of apomorphine (1 mg/kg) 1 week later to confirm the efficacy of the 6-OHDA stereotaxic injection and to select the mice that were presumably sufficiently lesioned (ie, mice that did not demonstrate rotations were not included in the behavioral tests) as described previously. 32 One week later, mice were injected with either vehicle or CIQ and, 90 minutes after the first and the seventh injections, were placed in a transparent glass cylinder (13 cm diameter, 24 cm height) to examine forelimb-use. We counted the number of times the mice touched the wall of the cylinder with their left forepaw (contralateral to the lesion) and right forepaw (ipsilateral to the lesion) during 5 minutes to evaluate forelimb-use asymmetry.
| Statistical analyses
Data are expressed as mean ± SEM with n indicating the number of slices or mice tested. Statistical significance of the results was assessed using the Student's t test for paired observations, the oneway ANOVA followed by Dunnett's multiple comparison test, or the two-way ANOVA followed by Bonferroni multiple comparison test.
Significant levels were set at P < 0.05.
| Materials
Chemicals and drugs were purchased from Sigma-Aldrich (Stockholm, 
| RESULTS
| Effect of CIQ on glutamatergic synaptic transmission
We first examined if CIQ altered glutamatergic synaptic transmission in the striatum by measuring fEPSP/PSs in mouse brain slices, as Figure 1A ,B,D). However, in the dopamine-depleted striatum, CIQ reversibly depressed the amplitude of the fEPSP/PS (68.9 ± 7.7% of baseline, n = 11 slices from 8 mice, P = 0.0031. Figure 1A ,B,D). This depressant action was mediated by GluN2C/2D-containing NMDARs because CIQ failed to reduce the fEPSP/PS amplitude in the presence of the GluN2C/2D antagonist UPB141 (6 μmol/L, 96.3 ± 7.2% of baseline, n = 9 slices from 6 mice, P = 0.5303. Figure 1B) . We sought to determine if the inhibition induced by CIQ in the dopaminedepleted striatum was mediated through a presynaptic mechanism.
We applied a paired-pulse stimulation protocol, a commonly used experimental design to investigate the ability of pharmacological compounds to modulate the release of glutamate. Both paired-pulse facilitation and paired-pulse depression have been observed in several brain regions and are determined by the release probability which can vary between different synapses 34 and within the striatum. 35, 36 In our experimental conditions, we found a paired-pulse synaptic depression, ie, the amplitude of the second fEPSP/PS is smaller than the amplitude of the first fEPSP/PS ( Figure 1C,D) . We found that CIQ did not affect the ratio between the second and the first fEPSP/PS in the intact striatum but increased this ratio in the dopamine-depleted striatum ( Figure 1C,D) . This change in the paired-pulse ratio indicates that CIQ modulates the release of glutamate at synapses onto striatal neurons. Thus, CIQ applied in the perfusion solution reversibly depresses glutamatergic synaptic transmission in the dopamine-depleted striatum, but not in the intact striatum, through presynaptic inhibition of glutamate release.
| Effect of CIQ on LTP induction
We then examined the effect of CIQ on a form of NMDARdependent synaptic plasticity, LTP, in the dorsolateral part of the striatum. After a stable fEPSP/PS amplitude was obtained, we applied a HFS consisting of 100-Hz trains of 1-second duration repeated 4 times with a 10-second inter-train interval. In the intact striatum, HFS induced a lasting increase in the amplitude of the fEPSP/PS (147.5 ± 14.2% baseline, n = 10 slices from 10 mice, P = 0.0161 Figure 2A ,C). This LTP was significantly reduced in the lesioned striatum (109.5 ± 4.0% baseline, n = 10 slices from 9 mice, P = 0.0541, Figure 2A ,C). We previously found that NMDARs are functional in the dopamine-depleted striatum although their overall activity is reduced. 16 We reasoned that HFS failed to trigger LTP because of an insufficient activation of NMDARs and that potentiating their activation might promote LTP induction. We first examined if CIQ applied in the perfusion solution during the entire recording session affected the ability of HFS to induce LTP in the dopamine-depleted striatum. We found that LTP was induced in the presence of CIQ (20 μmol/L, 134.5 ± 5.8% baseline, n = 10 slices from 5 mice, P = 0.0002, Figure 2C ). We then tested the effect of CIQ applied only before and during HFS, and we found that LTP was again rescued (147.9 ± 13.7% baseline, n = 8 slices from 7 mice, We have also investigated the effect of CIQ in slices from control mice. LTP was induced in control slices (142.7 ± 11.3% baseline, P = 0.0046, n = 11 slices from 8 mice) but was impaired in slices perfused with CIQ before and during HFS (100.9 ± 4.8% baseline, P = 0.5039, n = 8 slices from 4 mice, Figure 3 ).
CIQ crosses the blood-brain-barrier and was shown to modify specific behaviors and learning when administered systemically. Figure 5A ,C). LTP was lost in the dopamine-depleted striatum of vehicletreated mice (91.9 ± 6.9% baseline, n = 9 slices from 6 mice, P = 0.7649,
Figure 5B,C) and was fully induced in CIQ-treated mice (152.6 ± 10.8% baseline, n = 7 slices from 6 mice, P = 0.0021, Figure 5B ,C).
Thus, CIQ applied in the perfusion solution or administered systemically does not affect LTP in the intact striatum but rescues impaired LTP in the dopamine-depleted striatum.
| Effect of CIQ on forelimb-use asymmetry
We have used the cylinder test to examine if acute and chronic i.p.
injections of CIQ (10 mg/kg) could rescue forelimb-use asymmetry, However, vehicle-treated mice demonstrated forelimb-use asymmetry, ie, they used the forepaw contralateral to the lesion less frequently than the forepaw ipsilateral to the lesion (contralateral touches: 42.7 ± 2.9 and 41.0 ± 1.7% of total touches for acute and chronic vehicle, respectively, n = 11 mice, Figure 6 ). These values are within the range of those published earlier for mice that received a 6-OHDA injection in the substantia nigra. 38 Mice treated with CIQ used the left and right forepaws equally (contralateral touches:
47.9 ± 1.0 and 48.7 ± 1.0% of total touches for acute and chronic CIQ, respectively, n = 11 mice, Figure 6 ), and there was a significant difference between mice chronically treated with vehicle and mice chronically treated with CIQ (Two-way ANOVA analysis followed by Bonferroni multiple comparisons test, P = 0.0051, Figure 6 ).
These observations demonstrate that CIQ reverses forelimb-use asymmetry in 6-OHDA-lesioned mice.
| DISCUSSION
Our study demonstrates that a positive allosteric modulator of GluN2C/D-containing NMDARs rescues impaired LTP, a potential mechanism for cellular mechanism of motor learning, in the striatum of a mouse model of PD. Our results also show that CIQ reverses a behavioral impairment, ie, forelimb-use asymmetry, which is produced by unilateral striatal dopamine loss. Modulating the function of GluN2D-containing NMDARs might be a novel approach to reduce deficits in experimental Parkinsonism.
CIQ is a positive allosteric modulator of GluN2C/D-containing NMDARs, ie, it potentiates the action of glutamate, or of an agonist, on the NMDAR. In this study, glutamate released upon electrical stimulation is the agonist that activates NMDARs. Because GluN2C is absent from the striatum, 10 the effects of CIQ observed in our slice experiments are likely mediated by NMDARs that contain GluN2D in the striatum. CIQ was shown to potentiate NMDA responses in neurons which express GluN2D such as neurons in the subthalamic nucleus, cholinergic interneurons in the striatum, and medium spiny neurons in the dopamine-depleted striatum. CIQ does not potentiate NMDA responses in neurons which express mostly GluN2A and GluN2B, such as medium spiny neurons in the intact striatum and hippocampal pyramidal neurons. 26, 27, 30, 40 In this study, we found that CIQ depresses glutamatergic synaptic transmission in the dopamine-depleted striatum but not in the intact striatum. This finding is in agreement with the observed upregulation of GluN2D in the lesioned striatum. 16, 30 Indeed,
GluN2D is exclusively present in interneurons in the striatum of adult rodents but is upregulated and forms functional NMDARs in MSNs in the dopamine-depleted striatum. We previously found that NMDA applied in the perfusion solution depresses glutamatergic synaptic transmission in the striatum through a presynaptic mechanism. 15, 28, 33 Here, the inhibitory effect of CIQ also involves a presynaptic mechanism.
Thus, it is possible that potentiation of GluN2D-containing NMDARs by CIQ leads to the release of a retrograde signaling substance, such as adenosine, that acts on axon terminals to inhibit glutamate release, as shown previously for NMDA.
28
Because the presynaptic inhibitory action of CIQ is transient, we could examine the effect of this compound on the induction of LTP.
Our results show that HFS induces LTP of the fEPSP/PS in the striatum, which likely corresponds to an increased glutamatergic synaptic transmission and firing in projection neurons, as described in previous studies. 20, 41 In accordance with previous findings, 42 we found that LTP is lost in the dopamine-depleted striatum. In this study, we demonstrate that this impaired LTP is rescued by CIQ applied in the perfusion solution or administered systemically. It is unlikely that this rescued LTP by CIQ is due to residual dopamine released upon HFS and potentiated by CIQ, as shown previously in the partially lesioned striatum, 27 because LTP induction is highly sensitive to a reduction in striatal dopamine content and is impaired even in partially lesioned striatum. 13 The contribution of cholinergic interneurons is unlikely because, in the lesioned striatum, GluN2D is reduced in these interneurons, and CIQ does not increase their firing or NMDA-evoked currents. 16, 30 However, GluN2D
contributes to functional NMDARs in projection neurons in the dopamine-depleted striatum, but not in the dopamine-intact striatum, as a result of a switch between GluN2B and GluN2D. 16 Because the conductance and calcium permeability of NMDARs made of GluN2D are lower than those made of GluN2A and GluN2B, 4, 5 it is likely that the In this study, we demonstrate that chronic systemic administration of CIQ rescues a form of synaptic plasticity which is impaired in models of PD. Future studies will determine whether CIQ also rescues other forms of synaptic plasticity described in the striatum, such as LTP and LTD of AMPA receptor-mediated synaptic responses measured in projection neurons and in interneurons with whole-cell patch clamp recordings. Interestingly, systemic administration of CIQ also rescues a behavior which is specific for unilateral lesion of the dopaminergic pathway, ie, forelimb-use asymmetry.
Potentiation of NMDARs by CIQ in striatal projection neurons, which constitute 95% of the total striatal population, could contribute to the behavioral benefits obtained with CIQ. Indeed, the contribution of GluN2D to NMDARs is increased in these neurons in the dopamine-depleted striatum, 16 and we now demonstrate that LTP in the striatum is rescued by CIQ. However, GluN2D is expressed in other basal ganglia regions, ie, the subthalamic nucleus, substantia nigra, and globus pallidus. [43] [44] [45] The possible involvement of the subthalamic nucleus in the behavioral effect of CIQ is unlikely although CIQ was shown to potentiate NMDA responses in control mice. 43 Indeed, NMDAR antagonists infused in this brain region reverse locomotor deficits in the hemiparkinsonian rat. 46 It is unlikely that CIQ improves behavioral deficits by potentiating GluN2C- GluN2A and GluN2B are highly expressed in the striatum.
Interestingly, an article by Li et al 19 found that GluN2A, but not GluN2B, is involved in the induction of LTP in the dorsolateral striatum. These findings suggest that GluN2A could be targeted for the rescue of neurophysiological and behavioral impairments in models of PD. Future studies might reveal the ability of positive allosteric modulators of GluN2A-and GluN2B-containing NMDARs to rescue impairments in experimental Parkinsonism.
| CONCLUSIONS
We recently demonstrated that CIQ increases dopamine release from residual terminals in the partially dopamine-depleted striatum.
27
In this study, the use of CIQ allowed us to confirm dysfunctions of GluN2D-containing NMDARs in experimental Parkinsonism and to identify a novel way to pharmacologically rescue the loss of LTP and a behavioral impairment induced by unilateral dopamine depletion of the striatum. In light of our previously published observations, 15, 16, 27, 30 our results strengthen our suggestion that GluN2D is a potential target for the development of antiparkinsonian compounds.
